Study Summary
All participants in phase 1 and phase 2a had hand motion visual acuity or worse. If efficacy was demonstrated from phase 1, better vision subjects could be enrolled; however, efficacy was not demonstrated.
Want to learn more about this trial?
Request More InfoInterventions
AGN-151597DRUG
AGN-151597 is a gene therapeutic delivered by intravitreal injection
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| University of California San Francisco - Mission Bay /ID# 235717 | San Francisco | California | United States |
| Cincinnati Eye Institute- Edgewood /ID# 236713 | Edgewood | Kentucky | United States |
| Duke Eye Center /ID# 235715 | Durham | North Carolina | United States |
| Retina Foundation of the Southwest /ID# 235199 | Dallas | Texas | United States |